WO1995024503A1 - Sensitive cancer test - Google Patents
Sensitive cancer test Download PDFInfo
- Publication number
- WO1995024503A1 WO1995024503A1 PCT/EP1995/000823 EP9500823W WO9524503A1 WO 1995024503 A1 WO1995024503 A1 WO 1995024503A1 EP 9500823 W EP9500823 W EP 9500823W WO 9524503 A1 WO9524503 A1 WO 9524503A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tumor
- assay according
- assay
- gene
- expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
Definitions
- the assay is based on the use of a molecular marker, designated as Gene H19, which is used for in-situ hybridization of a tissue sample and for indicating the absence or presence of a cancer and its grading by a suitable marker (probe) . Also, a kit for carrying out such an assay is provided.
- biopsied tissues can detect minimal disease.
- H19 is an imprinted gene in human, expressed from the maternal allele. It is extensively transcribed early in embryogensis and in certain fetal tissues, and its expression is shut off in postnatal life. The expression of H19 parallels, in general, the expression of insulin-growth-factor 2, to which it is tightly linked on chromosome llpl5.5.
- the H19 gene does not encode
- RNA molecule for a protein and functions on an RNA molecule.
- H19 Relaxation of imprinting of H19 has been demonstrated in Wilms' tumor as well as in trophoblastic neoplasia.
- Two low-grade transitional cell tumors of the urinary bladder did not express the gene, like in bladder mocosa of the adult.
- Prominent expression of H19 was evident in 3 intermediate-grade and 4 high- grade transitional cell carcinomas and in in-situ bladder carcinoma adjacent to invasive tumor.
- H19 was found to be expressed in nephrogenic rests in a kidney of aniridia syndrome and in Wilms' tumor, as well as in 4/6 cases of embryonal rhabdomyosarcoma. Expression of H19 was noted in epithelial and mesenchymal elements of immature ovarian teratoma which developed after excision of dermoid cyst, while the original tumor did not express the gene. Prominent expression of this gene was also noted in certain elements of testicular germ cell and stromal-sex cord tumors . Genomic imprinting is a newly discovered mechanism in genetics by which certain traits are selectively expressed either from the maternal or from the paternal genome.
- Genomic imprinting plays a pivotal role in early stages of embryogensis and implantation as well as in fetal development. Our understanding of the scope of genomic imprinting is continuously expanding, and imprinted genes have been linked to an array of human diseases. Of major interest is the role of imprinted genes in the evolution of cancer.
- One of the genes proved to be imprinted in man is the H19 gene. It is located on chromosome llpl5.5, in close proximity to the gene of insulin-like growth factor 2 (IGF2), and is reciprocally imprinted: H19 is expressed from the maternal allele, while IGF2 is expressed from the paternal allele (Bartolomei 92).
- IGF2 insulin-like growth factor 2
- H19 is one of the most abundant mRNAs in the fetus, comprising up to 10% of the total mRNA in the placenta and certain tissues.
- the H19 gene does not encode for a protein, and presumably acts as a RNA molecule. In spite of extensive study, its function has remained an enigma. On the basis of loss of heterozygosity at llpl5.5 with retention of the paternal chromosome in Wilms ' tumor and embryonal rhabdomyosarcoma and in the cancer-predisposing syndrome of Beckwith-Wiedeman. It has been suggested that H19 should be considered a candidate for tumor suppressor gene.
- H19 is expressed from the maternal as well as the paternal alleles in about a third of Wilms' tumors.
- Shortly thereafter expression of H19 has been demonstrated in complete hydatidiform mole, which is placental tissue exclusively derived from androgenetic genome, and that gives rise to a malignant trophoblastic tumor - choriocarcinoma.
- This phenomenon of the aberrant expression of H19 from the paternal allele has been coined relaxation of imprinting.
- an extremely sensitive assay for the early detection of human cancer of various types.
- the assay is based on the use of a molecular marker, designated as Gene H19, which is used for in-situ hybridization of a tissue sample and for indicating the absence or presence of a cancer and its grading by a suitable marker (probe).
- a kit for carrying out such assay As set out above, there has been identified a molecular marker, a gene designated as H19, located on chromosome 11 in the vicinity of several cancer related genes.
- an assay is provided, based on in-situ hybridization (ISH) technique to analyze tissue sections for H19 expression.
- ISH in-situ hybridization
- ISH in-situ hybridization
- transitional cell tumors arising from the epithelium lining the urinary collecting system, is one of the most prevalent types of cancer in the human.
- the histopathologic grading of transitional cell neoplasma is based on their resemblance to the normal tissue and correlates well with their biologic behavior, including the potential to become invasive.
- H19 Prominent expression of H19 was found in the transitional epithelium of the renal pelvis and ureter and of the urinary bladder of the fetus but not in the bladder mucosa of the adult.
- H19 Pronounced expression of H19 was also noted in carcinoma in-situ of the bladder mucosa adjacent to invasive cancer.
- Wilms' tumor is a pediatric tumor of the kidney which resembles the fetal kidney and contains elements of the primitive metanephric blastema differentiating to tubular and/or glomerular structures admixed with mesenchymal stroma. Wilms' tumor is associated with several hereditary disorders, among which are Beckwith-Wiedemann syndrome, hemihypertrophy and the aniridia syndrome.
- H19 in the fetal kidney is prominent in the primitive metanephric blastema and is dramatically reduced with differentiation to tubular structures. In a kidney removed from a patient with aniridia syndrome. H19 expression was demonstrated in rests of metanephric blastema, while no expression was detected in the rest of the mature renal tissue. Expression of H19 was evident in Wilms' tumor, as already described by others.
- Embryonal rhabdomyosarcoma is a solid pediatric tumor with morphologic and biochemical markers of striated muscle at early stages of differentiation. During embryogenesis pronounced H19 expression is found in primitive niesenchyme and myoblasts of the developing muscular system of the human embryo, but the expression is markedly reduced with differentiation of myotubes . With formation of myofibers in the fetus in the second trimester of pregnancy H19 expression is again abundant with residual low expression postnatally.
- H19 expression was examined to 6 cases of embryonal rhab ⁇ domyosarcoma. The histologic diagnosis in all cases routinely included positive histochemical staining for muscle markers and/or electron microscopic study. H19 was found to be expressed in 4/6 embryonal rhabdomyosarcoma.
- H19 was found to be expressed in mesodermal and endormal elements in immature teratoma, but not in the preceding dermoid cyst compared to mature tissue elements.
- TESTICULAR GERM-CELL AND SEX-CORD-STROMAL TUMORS Prominent expression of H19 was found in certain components non- seminomatous germ cell tumor, but no expression was disclosed in seminomas .
- H19 probe for in-situ hybridization A part of the human H19 gene (800bp) was subcloned onto a plasmid. In-vitro transcription with T7 RNA polymerase was used to produce antisense H19 RNA from linearized plasmid DNA using [ 35 S] UTP nucleotide, and was purified by ethanolic precipitation.
- the slides were counterstained using Hematoxylin-eosin, examined and photographed using a light microscope under bright and dark field illumination. This method may be utilized for examination of histological and cytological slides from all tissues. To facilitate rapid laboratory examination the H19 antisense probe will be labeled with a fluorescentic tag or color which will shorten exposure tune to 24h.
- Fluorescentic labelling of another oncodevelopmental gene (IGF2) by a dye which emits fluorescent light at a different wavelength will allow visualization of both gene products on the same slide. Analysis of these slides requires only a fluorescence microcope.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/704,786 US5955273A (en) | 1994-03-07 | 1995-03-06 | Use of the H19 gene as a tumor marker |
AU18930/95A AU1893095A (en) | 1994-03-07 | 1995-03-06 | Sensitive cancer test |
DE69526855T DE69526855T2 (en) | 1994-03-07 | 1995-03-06 | Cancer test in which a probe derived from the H19 gene is used |
EP95927570A EP0759092B1 (en) | 1994-03-07 | 1995-03-06 | Cancer test comprising the use of a probe derived from the H19 gene |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL108879 | 1994-03-07 | ||
IL10887994A IL108879A (en) | 1994-03-07 | 1994-03-07 | Diagnostic assay for malignancies using the H19 gene and kit |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995024503A1 true WO1995024503A1 (en) | 1995-09-14 |
Family
ID=11065896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/000823 WO1995024503A1 (en) | 1994-03-07 | 1995-03-06 | Sensitive cancer test |
Country Status (7)
Country | Link |
---|---|
US (1) | US5955273A (en) |
EP (1) | EP0759092B1 (en) |
AU (1) | AU1893095A (en) |
DE (1) | DE69526855T2 (en) |
ES (1) | ES2177653T3 (en) |
IL (1) | IL108879A (en) |
WO (1) | WO1995024503A1 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0906448A1 (en) * | 1996-04-05 | 1999-04-07 | Thomas Jefferson University | Methods for the diagnosis and prognosis of cancer |
WO1999018195A2 (en) * | 1997-10-03 | 1999-04-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for inducing tumor-specific cytotoxicity |
WO2000000603A2 (en) * | 1998-06-26 | 2000-01-06 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Modularly constructed rna molecules having two sequence region types |
US7041654B2 (en) | 1997-10-03 | 2006-05-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for inducing tumor-specific cytotoxicity |
WO2007007317A1 (en) | 2005-07-07 | 2007-01-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nucleic acid agents for downregulating h19, and methods of using same |
WO2007034487A1 (en) | 2005-09-22 | 2007-03-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer |
US7928083B2 (en) | 2007-01-16 | 2011-04-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | H19 silencing nucleic acid agents for treating rheumatoid arthritis |
WO2016203476A1 (en) * | 2015-06-18 | 2016-12-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and compositions for diagnosing and treating urothelial cancer |
WO2018214249A1 (en) * | 2017-05-22 | 2018-11-29 | 立森印迹诊断技术(无锡)有限公司 | Imprinted gene grading model, system composed of same, and application of same |
CN108977535A (en) * | 2017-06-01 | 2018-12-11 | 立森印迹诊断技术(无锡)有限公司 | A kind of model and its application for detecting tumor of bladder degree of benign and malignant |
CN109423520A (en) * | 2017-08-31 | 2019-03-05 | 立森印迹诊断技术(无锡)有限公司 | A kind of hierarchy model and its application for detecting colorectal carcinoma degree of benign and malignant |
WO2019105381A1 (en) * | 2017-11-28 | 2019-06-06 | 立森印迹诊断技术有限公司 | Grading model for detecting benign and malignant degrees of breast turmors and application thereof |
WO2020011195A1 (en) * | 2018-07-13 | 2020-01-16 | 立森印迹诊断技术有限公司 | Grading model used for detecting degree to which lung tumors are benign and malignant, and application thereof |
WO2020052520A1 (en) * | 2018-09-10 | 2020-03-19 | 立森印迹诊断技术有限公司 | Hierarchical model for detecting benign and malignant degree of skin tumors and application thereof |
WO2020098604A1 (en) * | 2018-11-12 | 2020-05-22 | 立森印迹诊断技术有限公司 | Grading model for determining benign and malignant degree of prostate tumors and use thereof |
WO2020103905A1 (en) * | 2018-11-21 | 2020-05-28 | 立森印迹诊断技术有限公司 | Prognostic markers in lung cancer, prognostic typing model of lung cancer, and application thereof |
WO2021018116A1 (en) * | 2019-07-30 | 2021-02-04 | 立森印迹诊断技术有限公司 | Tumour marker and use thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004024957A2 (en) * | 2002-09-12 | 2004-03-25 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method for detection of micro-metastasis |
US7482156B2 (en) * | 2003-10-15 | 2009-01-27 | Cell Genesys, Inc. | Hepatocellular carcinoma specific promoter and uses thereof |
WO2008093331A1 (en) * | 2007-01-29 | 2008-08-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Antibody conjugates for circumventing multi-drug resistance |
US9173964B2 (en) * | 2007-10-25 | 2015-11-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Diphtheria toxin first open reading frame operably linked to an H19 promoter and a diphtheria toxin second open reading frame operably linked to an IGF-II promoter as nucleic acid construct |
-
1994
- 1994-03-07 IL IL10887994A patent/IL108879A/en not_active IP Right Cessation
-
1995
- 1995-03-06 EP EP95927570A patent/EP0759092B1/en not_active Expired - Lifetime
- 1995-03-06 US US08/704,786 patent/US5955273A/en not_active Expired - Lifetime
- 1995-03-06 WO PCT/EP1995/000823 patent/WO1995024503A1/en active IP Right Grant
- 1995-03-06 ES ES95927570T patent/ES2177653T3/en not_active Expired - Lifetime
- 1995-03-06 DE DE69526855T patent/DE69526855T2/en not_active Expired - Lifetime
- 1995-03-06 AU AU18930/95A patent/AU1893095A/en not_active Abandoned
Non-Patent Citations (7)
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0906448A1 (en) * | 1996-04-05 | 1999-04-07 | Thomas Jefferson University | Methods for the diagnosis and prognosis of cancer |
EP2014772A3 (en) * | 1996-04-05 | 2009-05-27 | Antonio Giordano | Method for the diagnosis and prognosis of cancer |
EP0906448A4 (en) * | 1996-04-05 | 2004-12-01 | Antonio Giordano | Methods for the diagnosis and prognosis of cancer |
JP2008136480A (en) * | 1997-10-03 | 2008-06-19 | Yissum Research Development Co Of The Hebrew Univ Of Jerusalem | Method and composition for inducing tumor-specific cytotoxicity |
WO1999018195A2 (en) * | 1997-10-03 | 1999-04-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for inducing tumor-specific cytotoxicity |
WO1999018195A3 (en) * | 1997-10-03 | 1999-08-12 | Yissum Res Dev Co | Methods and compositions for inducing tumor-specific cytotoxicity |
US6306833B1 (en) | 1997-10-03 | 2001-10-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for inducing tumor-specific cytotoxicity |
AU755774B2 (en) * | 1997-10-03 | 2002-12-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for inducing tumor-specific cytotoxicity |
US7041654B2 (en) | 1997-10-03 | 2006-05-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for inducing tumor-specific cytotoxicity |
WO2000000603A2 (en) * | 1998-06-26 | 2000-01-06 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Modularly constructed rna molecules having two sequence region types |
WO2000000603A3 (en) * | 1998-06-26 | 2000-04-13 | Deutsches Krebsforsch | Modularly constructed rna molecules having two sequence region types |
US8067573B2 (en) | 2005-07-07 | 2011-11-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nucleic acid agents for downregulating H19 and methods of using same |
WO2007007317A1 (en) | 2005-07-07 | 2007-01-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nucleic acid agents for downregulating h19, and methods of using same |
US8067574B2 (en) | 2005-07-07 | 2011-11-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nucleic acid agents for downregulating H19, and methods of using same |
US8034914B2 (en) | 2005-09-22 | 2011-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer |
WO2007034487A1 (en) | 2005-09-22 | 2007-03-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer |
US7928083B2 (en) | 2007-01-16 | 2011-04-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | H19 silencing nucleic acid agents for treating rheumatoid arthritis |
WO2016203476A1 (en) * | 2015-06-18 | 2016-12-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and compositions for diagnosing and treating urothelial cancer |
WO2018214249A1 (en) * | 2017-05-22 | 2018-11-29 | 立森印迹诊断技术(无锡)有限公司 | Imprinted gene grading model, system composed of same, and application of same |
CN108929851A (en) * | 2017-05-22 | 2018-12-04 | 立森印迹诊断技术(无锡)有限公司 | A kind of model and its application for detecting benign from malignant tumors degree |
CN108977535A (en) * | 2017-06-01 | 2018-12-11 | 立森印迹诊断技术(无锡)有限公司 | A kind of model and its application for detecting tumor of bladder degree of benign and malignant |
CN109423520A (en) * | 2017-08-31 | 2019-03-05 | 立森印迹诊断技术(无锡)有限公司 | A kind of hierarchy model and its application for detecting colorectal carcinoma degree of benign and malignant |
WO2019041689A1 (en) * | 2017-08-31 | 2019-03-07 | 立森印迹诊断技术(无锡)有限公司 | Imprinted gene grading model for colorectal tumours and system composed of same |
WO2019105381A1 (en) * | 2017-11-28 | 2019-06-06 | 立森印迹诊断技术有限公司 | Grading model for detecting benign and malignant degrees of breast turmors and application thereof |
WO2020011195A1 (en) * | 2018-07-13 | 2020-01-16 | 立森印迹诊断技术有限公司 | Grading model used for detecting degree to which lung tumors are benign and malignant, and application thereof |
WO2020052520A1 (en) * | 2018-09-10 | 2020-03-19 | 立森印迹诊断技术有限公司 | Hierarchical model for detecting benign and malignant degree of skin tumors and application thereof |
WO2020098604A1 (en) * | 2018-11-12 | 2020-05-22 | 立森印迹诊断技术有限公司 | Grading model for determining benign and malignant degree of prostate tumors and use thereof |
WO2020103905A1 (en) * | 2018-11-21 | 2020-05-28 | 立森印迹诊断技术有限公司 | Prognostic markers in lung cancer, prognostic typing model of lung cancer, and application thereof |
WO2021018116A1 (en) * | 2019-07-30 | 2021-02-04 | 立森印迹诊断技术有限公司 | Tumour marker and use thereof |
Also Published As
Publication number | Publication date |
---|---|
EP0759092A1 (en) | 1997-02-26 |
IL108879A0 (en) | 1994-06-24 |
EP0759092B1 (en) | 2002-05-29 |
DE69526855D1 (en) | 2002-07-04 |
AU1893095A (en) | 1995-09-25 |
IL108879A (en) | 2000-08-31 |
DE69526855T2 (en) | 2002-11-28 |
ES2177653T3 (en) | 2002-12-16 |
US5955273A (en) | 1999-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0759092B1 (en) | Cancer test comprising the use of a probe derived from the H19 gene | |
Hartmann et al. | Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma | |
JP4517152B2 (en) | Methods and compositions for chromosome-specific staining | |
US7820386B2 (en) | Cancer screening method | |
US9493839B2 (en) | Non-invasive cancer diagnosis | |
JP6203752B2 (en) | Materials and methods for diagnosis, prediction and evaluation of prostate cancer therapeutic / preventive treatment | |
Sauter et al. | DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH | |
CN114672568B (en) | Kit for detecting cervical cell gene methylation | |
US20120135877A1 (en) | DNA Methylation Markers For Prostate Cancer Field Defect | |
Kiechle et al. | Genetic imbalances in precursor lesions of endometrial cancer detected by comparative genomic hybridization | |
EP1464709B1 (en) | Detection of HPV-induced invasive cancers and their precursor lesions with invasive potential | |
KR20050100371A (en) | Methods of detecting gene expression in normal and cancerous cells | |
Junker et al. | Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer | |
CN111500731A (en) | Kit for early diagnosis, detection or screening of thyroid cancer, and use method and application thereof | |
US6689614B1 (en) | Method of identifying and treating invasive carcinomas | |
Neves et al. | Prospective evaluation of genetic abnormalities and telomerase expression in exfoliated urinary cells for bladder cancer detection | |
Sneige et al. | Interphase cytogenetics in mammographically detected breast lesions | |
Xu et al. | Epithelioid trophoblastic tumor: comparative genomic hybridization and diagnostic DNA genotyping | |
Muzio et al. | Morphometric study of nucleolar organiser regions (AgNOR) in HPV-associated precancerous lesions and microinvasive carcinoma of the oral cavity | |
Miyake et al. | Highly specific and sensitive detection of malignancy in urine samples from patients with urothelial cancer by CD44v8–10/CD44v10 competitive RT‐PCR | |
Hui et al. | Comparative genomic hybridization study of placental site trophoblastic tumour: a report of four cases | |
US7811752B2 (en) | Plasma or serum marker and process for detection of cancer | |
CN111100930B (en) | Grading model for detecting benign and malignant degree of pancreatic tumor and application thereof | |
CN111549136A (en) | Kit for thyroid cancer detection and using method and application thereof | |
Lalani et al. | Prostate cancer; the interface between pathology and basic scientific research |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CZ FI HU JP KR MX NZ PL RO RU SK UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 08704786 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995927570 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995927570 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995927570 Country of ref document: EP |